Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

Circulation

Volumn 108, Issue 4, 2003, Pages 414-419

  Sattar, Naveed ^a   Gaw, Allan ^a   Scherbakova, Olga ^b   Ford, Ian ^b   O'Reilly, Denis St J ^a   Haffner, Steven M ^c   Isles, Chris ^d   Macfarlane, Peter W ^a   Packard, Chris J ^a   Cobbe, Stuart M ^a   Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary disease; Glucose; Inflammation; Insulin; Obesity

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATION PROGRAM; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYNDROME; UNITED KINGDOM;

BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SCOTLAND; TRIGLYCERIDES;

EID: 0042665536     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000080897.52664.94     Document Type: Article

References (27)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;16:356-359.
5. Shepherd J, Cobbe SM, Ford I, et. al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
6. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
7. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-1600.
8. Han TS, Williams K, Sattar N, et al. Prospective analysis of obesity, body fat distribution and hyperinsulinaemia in the development of metabolic syndrome in the San Antonio Heart Study. Obes Res. 2002;10:923-931.
9. Sattar N, Tan CE, Han T, et al. Association of indices of adiposity with the atherogenic lipoprotein profile. Int J Obes. 1998;22:432-439.
10. Wei M, Gaskill SP, Haffner SM, et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 7-year prospective study. Obes Res. 1997;5:16-23.
11. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res. 2001;9:696-705.
12. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes. 2001;25:1047-1056.
13. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391-397.
14. Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation. 2002;105:2583-2585.
15. Ridker PM. Role of inflammatory biomarkers in prediction of coronary heart disease. Lancet. 2001;358:946-948.
16. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
17. Festa A, D'Agostino R Jr, Tracy RP, et al. The Insulin Resistance Atherosclerosis Study: elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-1137.
18. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046-3051.
19. WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Study. Am J Cardiol. 1995;76:485-491.
20. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
21. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ. 1995;311:158-161.
22. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
23. Joint British recommendations on prevention of coronary heart disease in clinical practice: British Cardiac Society, British Hyperlipidaemia Association. British Hypertension Society, endorsed by the British Diabetic Association. Heart. 1998;80(suppl 2):S1-S29.
24. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
25. Tuomilehto J, Lindström J, Erickson JG, et al, for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
26. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group: acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
27. Lakka HM, Laaksonen DE, Lakka TA, el al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.